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Reply to the Editor:
We thank Drs Szentkiralyi, Péterffy, and
Galajda for their thoughtful comments
about suture techniques for tricuspid valve
repair. We believe, as they do, that every
case of moderate tricuspid regurgitation
should be repaired. The options are numer-
ous, but we believe that the suture annulo-
plasty technique we described in this article
will be very successful in these cases. The
implication of their letter is that a suture
annuloplasty likewise would be equal for
very severe cases. We have tended to use a
rigid ring for very severe cases with obvi-
ous clinical manifestation of massive tri-
cuspid insufficiency.
The suture bicuspidization technique de-
scribed can be performed in less then 10
minutes. This technique is effective, reduces
the expense of operations, and certainly
should stimulate the use of a simple repair
techniques in every patient with moderate to
moderately severe tricuspid regurgitation.
Lawrence H. Cohn, MD
Department of Surgery
Brigham and Women’s Hospital
Boston, Mass
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Intraoperative oral sildenafil
for management of pulmonary
hypertension: A stepping stone
to the future
To the Editor:
I read with great interest the recent article
by Dr Shim and colleagues1 detailing their
experience with oral sildenafil in intraop-
erative pulmonary hypertension (N  53).
Although they controlled for confounders
such as anesthetic depth, hypercarbia, and
serum pH, it is not clear whether they ad-
equately controlled for hyperoxia, a potent
pulmonary vasodilator.2
In their Methods section, they specify
that all patients’ lungs were ventilated with
60% oxygen with standardized mechanical
ventilation, but they fail to report what
range of blood oxygen tensions were ob-
tained and whether they varied signifi-
cantly between study groups. Thus, a major
confounder is not adequately accounted for
in this otherwise interesting paper.
A second limitation with the implemen-
tation of the study findings into one’s prac-
tice is that oral sildenafil is not as conve-
nient in the intraoperative period as is an
inhalational or intravenous formulation.1,2
Because these formulations of sildenafil
exist, this study paves the way for their
investigation in the management of intra-
operative pulmonary hypertension, a
common scenario in patients undergoing
cardiac surgery.
It would be no surprise that these for-
mulations of sildenafil are demonstrated to
be clinically effective pulmonary vasodila-
tors. Of far more clinical importance would
be the clinical trials looking at synergistic
combinations of selective pulmonary vaso-
dilators. There are at least 4 different path-
ways that can be manipulated for synergis-
tic selective pulmonary vasodilation2:
1. Cyclic adenosine monophosphate
pathway with inhaled prostaglandin I2
2. Cyclic guanosine monophosphate
pathway with inhaled nitric oxide
3. Phosphodiesterase 5 inhibition with
sildenafil
4. Endothelin blockade with drugs
such as bosentan
The future is in synergistic approaches to
the management of pulmonary hyperten-
sion, just as we have seen in the manage-
ment of systemic hypertension over the
past 30 years.
I congratulate Dr Shim and colleagues
on a thought-provoking study. I look for-
ward to their feedback about these intraop-
erative considerations.
John G. T. Augoustides MD, FASE
Assistant Professor
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, Pa
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Reply to the Editor:
We appreciate the constructive comments
by Dr Augoustides regarding our study.1
He raised the issue of whether hyperoxia,
which is a potent pulmonary vasodilator,
was adequately controlled between the
control and sildenafil groups in our study.
The arterial oxygen tension (PaO2) levels
were 271  89 mm Hg versus 254  108
mm Hg (P  .602) before the first hemo-
dynamic measurement and 276  48 mm
Hg versus 235  55 mm Hg (P  .03)
immediately after the last measurement
with 60% oxygen in the control and silde-
nafil groups, respectively. There were no
significant changes in the PaO2 values
within each group.
Hypoxic pulmonary vasoconstriction
has been well studied for decades, with the
stimulus identified as both mixed venous
and alveolar oxygen tension in small arter-
ies and systemic PaO2 in large pulmonary
vessels.2 However, no comprehensive data
exist regarding graded response of the pul-
monary vasculature to changes in PaO2
above 120 mm Hg (hyperoxia), especially
in patients with long-standing valvular
heart disease with concomitant pulmonary
hypertension, as in our study. In an animal
study, Rudolph and Yuan3 studied the re-
lationship between PaO2 and pulmonary
vascular resistance and demonstrated that
there is no further decrease in pulmonary
vascular resistance above the PaO2 of 50 to
60 mm Hg. Therefore, although the PaO2
was lower in the sildenafil group after the
last measurement, this should not have any
further clinically significant effects on the
pulmonary vascular resistance.
We agree with Augoustides that proper
control of PaO2 between the groups should
be mentioned to clarify any confounding
factors.
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